

PRESSOR	MECHANISM	RISKS	INDICATION	DOSING
Norepinephrine	<ul style="list-style-type: none"> - α-1 and α-2 agonism (balanced venous and arterial vasoconstrictor) - Small amount of β-1 stimulation (increased chronotropy) 	<ul style="list-style-type: none"> - Considered to be safer than other pressor choices - Cardiac myocyte toxicity, cardiac arrhythmia, tissue ischemia 	1 st -line: septic, neurogenic, cardiogenic shock	2-4 mcg/min, titrate to effect
Epinephrine	<ul style="list-style-type: none"> - β-1 and β-2 agonism (increased inotropy and chronotropy, with small amount of bronchodilation) - Small amount of α-1 agonism, leading to peripheral vasoconstriction 	<ul style="list-style-type: none"> - Tachycardia - Lactic acidosis (unclear whether this is clinically significant) 	1 st -line: anaphylaxis 2 nd -line: sepsis *Avoid in cardiogenic shock	Anaphylaxis: 0.1 mg bolus, then 2-15 mcg/min Sepsis: 0.05 mcg/kg/min – 2 mcg/kg/min
Dopamine	<ul style="list-style-type: none"> - Low doses: dopaminergic agonism (renal vasodilation, increased GFR; can lower BP) - Moderate doses: β-1 agonism (inotropy and chronotropy) - High doses: α-1 agonism (vasoconstriction) 	<ul style="list-style-type: none"> **High risk for dysrhythmias - Possibly independently associated with increased mortality 	Rarely indicated 2 nd -line: shock refractory to other pressors	2-20mcg/kg/min
Dobutamine	<ul style="list-style-type: none"> - β-1 >> β-2 agonism (predominantly inotropic effects, with small amount of vasodilation and chronotropy) - High doses: mild α-1 agonism 	<ul style="list-style-type: none"> - Increased myocardial oxygen demand, arrhythmias - Possible hypotension - Only use if fully fluid resuscitated or with vasopressor 	<ul style="list-style-type: none"> - Septic shock with decreased cardiac output (despite adequate fluid resuscitation) - Possibly first line for cardiogenic shock after MI 	2-20 mcg/kg/min
Milrinone	<ul style="list-style-type: none"> - PDE3 inhibition (ultimately leads to cardiac smooth muscle relaxation and peripheral vasoconstriction) - No beta-adrenergic activity, so minimal chronotropy 	<ul style="list-style-type: none"> - Hypotension (only use after fully fluid resuscitated, and/or with vasopressor) - Sustained hypotension, dysrhythmias - Avoid in patients with renal disease 	<ul style="list-style-type: none"> - Exact indication is unclear - Daily beta-blocker use, catecholamine resistance - Possible role in patients with pulmonary HTN 	<ul style="list-style-type: none"> - NEVER bolus - Dose based on renal function - General range: 0.25-0.75 mcg/kg/min
Vasopressin	<ul style="list-style-type: none"> - Directly stimulates vasopressin receptors in kidney (efferent arteriole constriction → increased GFR) - peripheral vasculature (vasoconstriction) 	<ul style="list-style-type: none"> - Increased risk for digital ischemia (higher risk than catecholamine derivatives), especially when given with epinephrine 	<ul style="list-style-type: none"> - 2nd-line: septic shock - May be useful (but role not well-established): cardiogenic shock, pulmonary hypertension 	0.04 U/min (set dose; no bolus, no titration)
Phenylephrine	<ul style="list-style-type: none"> - Pure α-1 agonism (vasoconstriction) 	<ul style="list-style-type: none"> - Reflex bradycardia (only give with a chronotropic agent, to avoid this effect!) - Digital ischemia - Possibly worsened cardiac function, end-organ perfusion 	<ul style="list-style-type: none"> - Never use as a single agent - May be used with norepinephrine in neurogenic shock - May serve a role in vasodilatory hypotension due to medication overdose 	Start at 100-180 mcg/min, then titrate to maintenance (40-60 mcg/min) -Can administer 50-200 mcg q20min PRN

Type of Shock	Pressor recommendation (and dose)
Septic	<p>1st line: norepinephrine (2-4 mcg/min, titrate to effect)</p> <p>2nd line: Vasopressin (0.04 U/min) or epinephrine (0.05 – 2 mcg/kg/min)</p> <p>*Septic shock with evidence of decreased cardiac output, with adequate fluid resuscitation: consider dobutamine (2-20 mcg/kg/min)</p>
Cardiogenic	<p>**Controversial</p> <p><u>SBP 70-100 mmHg:</u></p> <p>1st line: dobutamine (2-20 mcg/kg/min)</p> <p>2nd line: norepinephrine (2-4 mcg/min, titrate to effect)</p> <p>3rd line: milrinone (controversial) (0.25-0.75 mcg/kg/min; be cautious in renal disease)</p> <p><u>SBP <70 mmHg:</u></p> <p>1st line: norepinephrine</p> <p>*Patients with daily beta-blocker use and/or long-standing heart failure: consider milrinone</p> <p>*Vasopressin's role in cardiogenic shock is not well-established, but it may be beneficial</p>
Neurogenic	<p>1st line: norepinephrine (2-20 mcg/min)</p> <p>2nd line: Phenylephrine (only use as adjunct to norepinephrine) (initially 100-180 mcg/min, titrate to 40-60 mcg/min maintenance; bolus 50-200 mcg q20min PRN)</p>
Anaphylactic	<p>1st line: epinephrine (initial bolus of 0.1 mg (1:10,000) over 5 minutes, followed by an infusion of 2-15 mcg/min)</p>